Pulse Biosciences (NASDAQ:PLSE) Raised to Sell at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report sent to investors on Tuesday.

Pulse Biosciences Price Performance

Pulse Biosciences stock opened at $17.74 on Tuesday. Pulse Biosciences has a fifty-two week low of $5.22 and a fifty-two week high of $22.69. The stock has a fifty day moving average of $17.35 and a two-hundred day moving average of $14.91.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the previous year, the firm posted ($0.19) earnings per share.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently modified their holdings of PLSE. Vanguard Group Inc. raised its holdings in Pulse Biosciences by 28.8% in the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after acquiring an additional 189,227 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after buying an additional 97,565 shares during the last quarter. Westside Investment Management Inc. grew its holdings in Pulse Biosciences by 97.8% in the 2nd quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after buying an additional 31,440 shares during the period. Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences during the 1st quarter valued at about $109,000. Finally, Creative Planning lifted its holdings in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after acquiring an additional 11,667 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.